Keywords: GlaxoSmithKline, Avandia, FDA, Heart attack risk

GlaxoSmithKline “knew about heart attack risks of Avandia,” claim US Senators, who also slam FDA

Article | 22 February 2010

Print This

A US Senate committee has alleged that UK drugs giant GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) poses increased risk of heart ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in